{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:29:59Z","timestamp":1786984199516,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005809","name":"Hyderabad Eye Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ajo.2025.12.007","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:40:15Z","timestamp":1765471215000},"page":"149-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A Randomized-Controlled Trial of the Efficacy, Safety and Tolerability of Intravitreal Brolucizumab in Patients With Chronic Central Serous Chorioretinopathy With Persistent Fluid in the Absence of Choroidal Neovascular Membrane\u2014BRICS Trial Report II"],"prefix":"10.1016","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3139-608X","authenticated-orcid":false,"given":"Srishti Raksheeth","family":"Ramamurthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-4560","authenticated-orcid":false,"given":"Saarang","family":"Hansraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragu","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-0178","authenticated-orcid":false,"given":"Ritesh","family":"Narula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-3306","authenticated-orcid":false,"given":"SriniVas R.","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay K.","family":"Chhablani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9211-917X","authenticated-orcid":false,"given":"Mudit","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikitha Gurram","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6812-1894","authenticated-orcid":false,"given":"Umesh Chandra","family":"Behera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9688-5859","authenticated-orcid":false,"given":"Raja","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2025.12.007_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100865","article-title":"Central serous chorioretinopathy: an update on risk factors, pathophysiology and imaging modalities","volume":"79","author":"Kaye","year":"2020","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"10.1016\/j.ajo.2025.12.007_bib0002","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","article-title":"Central serous chorioretinopathy","volume":"86","author":"Wang","year":"2008","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1016\/j.ajo.2025.12.007_bib0003","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich","year":"2015","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.007_bib0004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00006982-200202000-00004","article-title":"Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy","volume":"22","author":"Loo","year":"2002","journal-title":"Retina Phila Pa"},{"issue":"11","key":"10.1016\/j.ajo.2025.12.007_bib0005","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.oret.2020.07.026","article-title":"Multimodal imaging-based central serous chorioretinopathy classification","volume":"4","author":"Chhablani","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.007_bib0006","first-page":"6","article-title":"Cystoid macular degeneration in chronic central serous chorioretinopathy","volume":"23","author":"Iida","year":"2003","journal-title":"Retina Phila Pa"},{"key":"10.1016\/j.ajo.2025.12.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.07.003","article-title":"Central serous chorioretinopathy: towards an evidence-based treatment guideline","volume":"73","author":"van Rijssen","year":"2019","journal-title":"Prog Retin Eye Res"},{"issue":"10220","key":"10.1016\/j.ajo.2025.12.007_bib0008","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","article-title":"Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial","volume":"395","author":"Lotery","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"10","key":"10.1016\/j.ajo.2025.12.007_bib0009","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","article-title":"Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: The PLACE trial","volume":"125","author":"van Dijk","year":"2018","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2025.12.007_bib0010","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ajo.2006.04.028","article-title":"choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization","volume":"142","author":"Isola","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2025.12.007_bib0011","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ophtha.2024.09.003","article-title":"Therapies for central serous chorioretinopathy: a report by the American Academy of Ophthalmology","volume":"132","author":"Kim","year":"2025","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2025.12.007_bib0012","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/08820538.2024.2308808","article-title":"Intravitreal brolucizumab for chronic central serous chorioretinopathy without choroidal neovascular membrane: a pilot study","volume":"39","author":"Ramamurthy","year":"2024","journal-title":"Semin Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2025.12.007_bib0013","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2025.12.007_bib0014","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4103\/IJO.IJO_2973_23","article-title":"Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group","volume":"72","author":"Agarwal","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.12.007_bib0015","first-page":"1","article-title":"Protocol for a randomized controlled trial comparing intravitreal brolucizumab with placebo for chronic central serous chorioretinopathy with persistent macular fluid without choroidal neovascular membrane\u2014BRICS report #1","author":"Ramamurthy","year":"2025","journal-title":"Semin Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2025.12.007_bib0016","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","article-title":"Pharmacokinetics and Metabolism of [14C]Eplerenone after Oral Administration to Humans","volume":"31","author":"Cook","year":"2003","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"2","key":"10.1016\/j.ajo.2025.12.007_bib0017","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08998280.2004.11927973","article-title":"Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure","volume":"17","author":"Craft","year":"2004","journal-title":"Proc Bayl Univ Med Cent"},{"key":"10.1016\/j.ajo.2025.12.007_bib0018","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajo.2024.02.025","article-title":"Inner choroidal fibrosis: an optical coherence tomography biomarker of severity in chronic central serous chorioretinopathy","volume":"264","author":"Hansraj","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"16","key":"10.1016\/j.ajo.2025.12.007_bib0019","first-page":"3306","article-title":"Randomized controlled trials in central serous chorioretinopathy: a review","volume":"37","author":"Singh","year":"2023","journal-title":"Eye Lond Engl"},{"key":"10.1016\/j.ajo.2025.12.007_bib0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ajo.2021.06.020","article-title":"Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial","volume":"233","author":"van Rijssen","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2025.12.007_bib0021","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/bjophthalmol-2018-313048","article-title":"Optical coherence tomography angiography findings in cystoid macular degeneration associated with central serous chorioretinopathy","volume":"103","author":"Sahoo","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.12.007_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.survophthal.2025.09.017","article-title":"Double layer sign in chorioretinal diseases: clinical significance and implications from multimodal imaging","volume":"71","author":"Quarta","year":"2025","journal-title":"Surv Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2025.12.007_bib0023","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1007\/s00417-024-06578-8","article-title":"One-year choroidal thickness changes after photodynamic therapy for central serous chorioretinopathy evaluated by widefield optical coherence tomography","volume":"262","author":"Sawaguchi","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2025.12.007_bib0024","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ajo.2020.04.022","article-title":"Choroidal anatomic alterations after photodynamic therapy for chronic central serous chorioretinopathy: a multicenter study","volume":"217","author":"Iovino","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.007_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-37802-w","article-title":"Extensive reduction in choroidal thickness after photodynamic therapy in eyes with central serous chorioretinopathy","volume":"13","author":"Nishigori","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ajo.2025.12.007_bib0026","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","article-title":"Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results","volume":"123","author":"Koizumi","year":"2016","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2025.12.007_bib0027","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00417-021-05517-1","article-title":"Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study","volume":"260","author":"Tamashiro","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2025.12.007_bib0028","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11096-017-0460-4","article-title":"Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis","volume":"39","author":"Ji","year":"2017","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"10.1016\/j.ajo.2025.12.007_bib0029","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.survophthal.2023.03.001","article-title":"Comparing interventions for chronic central serous chorioretinopathy: a network meta-analysis","volume":"68","author":"You","year":"2023","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2025.12.007_bib0030","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00417-010-1581-9","article-title":"The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy","volume":"249","author":"Lim","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.12.007_bib0031","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ophtha.2013.09.024","article-title":"Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial","volume":"121","author":"Bae","year":"2014","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2025.12.007_bib0032","first-page":"732","article-title":"Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients","volume":"29","author":"Kim","year":"2015","journal-title":"Eye Lond Engl"},{"issue":"6","key":"10.1016\/j.ajo.2025.12.007_bib0033","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/bjophthalmol-2014-306018","article-title":"A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study","volume":"99","author":"Pitcher","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.12.007_bib0034","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.2147\/OPTH.S550375","article-title":"Efficacy and safety of intravitreal brolucizumab in chronic central serous chorioretinopathy: a retrospective cohort study","volume":"19","author":"Chakraborty","year":"2025","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2025.12.007_bib0035","article-title":"Resolution of subretinal fluid in intractable central serous chorioretinopathy with high-dose intravitreal aflibercept","volume":"37","author":"Lin","year":"2025","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"6","key":"10.1016\/j.ajo.2025.12.007_bib0036","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00417-024-06373-5","article-title":"Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy","volume":"262","author":"Huang","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.007_bib0037","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41598-024-52315-w","article-title":"Choroidal remodeling following different anti-VEGF therapies in neovascular AMD","volume":"14","author":"Boscia","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajo.2025.12.007_bib0038","article-title":"Comparison of one-year outcomes between aflibercept and brolucizumab for treatment-na\u00efve pachychoroid neovasculopathy","volume":"15","author":"Jeong","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.007_bib0039","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","article-title":"Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS registry and Komodo Healthcare Map","volume":"140","author":"Khanani","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.12.007_bib0040","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.oret.2021.05.003","article-title":"Clinical characteristics and outcomes of eyes with intraocular inflammation after Brolucizumab: post hoc analysis of HAWK and HARRIER","volume":"6","author":"Singer","year":"2022","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"10.1016\/j.ajo.2025.12.007_bib0041","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1080\/10543406.2011.592233","article-title":"Correcting overall survival for the impact of crossover via a rank-preserving structural failure time (RPSFT) model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma","volume":"22","author":"Korhonen","year":"2012","journal-title":"J Biopharm Stat"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425006579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425006579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:13:33Z","timestamp":1781788413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425006579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"alternative-id":["S0002939425006579"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.12.007","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized-Controlled Trial of the Efficacy, Safety and Tolerability of Intravitreal Brolucizumab in Patients With Chronic Central Serous Chorioretinopathy With Persistent Fluid in the Absence of Choroidal Neovascular Membrane\u2014BRICS Trial Report II","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}